Immunic | 8-K:雇佣协议
Immunic | 4/A:持股变动声明(修正)-高管 Nash Duane
Immunic | 4:持股变动声明-高管 Vitt Daniel
Immunic | 4:持股变动声明-高管 Tardio Jason
Immunic | 4:持股变动声明-高管 Muehler Andreas
Immunic | 4:持股变动声明-高管 Nash Duane
Immunic | 4:持股变动声明-高管 Whaley Glenn
Immunic | SC 13G/A:超过5%持股股东披露文件(修正)-Avidity Partners Management LP(9.9%),Avidity Partners Management (GP) LLC(9.9%)等
Immunic | SC 13G/A:超过5%持股股东披露文件(修正)-Janus Henderson Group plc(5.7%),Janus Henderson Biotech Innovation Master Fund Ltd(5.2%)
Immunic | SC 13G/A:超过5%持股股东披露文件(修正)-RTW Investments, LP(6.1%),Roderick Wong, M.D.(6.1%)
Immunic | 4:持股变动声明-董事 Rudick Richard Alan
Immunic | SC 13G/A:超过5%持股股东披露文件(修正)-The Vanguard Group(5.21%)
Immunic | SC 13G:超过5%持股股东披露文件-Adage Capital Management, L.P.(6.21%),Robert Atchinson(6.21%)等
Immunic | 10-Q:2024财年三季报
Immunic | 8-K:Immunic, Inc. 公布2024年第三季度财务业绩并提供公司最新情况
Immunic | SC 13G/A:超过5%持股股东披露文件(修正)-The Vanguard Group(5.21%)
Immunic | 8-K:Immunic宣布Vidofludimus钙治疗复发性多发性硬化症第三阶段ENSURE计划中期分析取得积极成果
Immunic | 8-K:Immunic举办了多发性硬化症研究与开发日
Immunic | 8-K:《就业协议》附录六
Immunic | 10-Q:2024财年二季报
暂无数据